Acumen (ABOS) Q2 FY26 earnings call

Acumen Pharmaceuticals remains focused on advancing sabirnetug towards its critical Phase II ALTITUDE-AD topline readout expected late this year, which will test the central scientific thesis of selectively targeting amyloid-beta oligomers. The company also progressed its enhanced brain delivery program with two nominated candidates, ACU301 and ACU401, aiming for an IND filing in mid-2027, expanding pipeline optionality.